2026 Pharma & Biotech Patent Litigation Summit

Partner Jackie Mulryne will be speaking at the 2026 Pharma & Biotech Patent Litigation Summit in Amsterdam as part of the panel Global Regulatory Exclusivities and Litigation for the Pharma and Biotech Sector. Jackie will share her insights on the impact of the EU pharmaceutical package covering exclusivity, compulsory licences, and supplementary protection certificates.

The panelists will:

• Assess proposed reforms to data exclusivity periods and their implications for generic market entry and incentives for innovation
• Examine the introduction of compulsory licences in emergency situations and the resulting litigation risks for originators
• Evaluate the EU’s push for a centralised unitary SPC system and how it may alter enforcement and harmonisation